EUCTR2004-001680-22-SE进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24mg) administered once daily for 12 weeks in subjects with fibromyalgia.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Subject is a male or female outpatient, at least 18 years of age.
- •A female is eligible to enter and participate in the study if she is of:
- •a Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal); or,
- •b Childbearing potential, has a negative result on all required pregnancy tests prior to randomization, and agrees to an acceptable contraceptive method as defined in the protocol.
- •2. Subject has a diagnosis of fibromyalgia as confirmed by the American College of Rheumatology (ACR) criteria.
- •3. Subject has baseline PI-NRS score averaging greater than or equal to 4 during the week prior to randomization (Baseline Period) and at least four pain intensity observations are recorded during the 7 days of the Baseline Period.
- •4. Subject is considered clinically appropriate for therapy with ropinirole based upon the Investigator’s overall clinical evaluation.
- •5. Subject is in good general health apart from fibromyalgia, as determined by the Investigator (based upon the physical and laboratory examinations, ECG and medical history).
- •6. Subject is able to comprehend the study procedures and schedule and is able to comply with study requirements.
- •7. Subject has given informed consent prior to participation in the study. The contents and process of obtaining informed consent will be in accordance with all applicable regulatory requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1. Other chronic pain condition(s) not associated with FMS.
- •2. Unable to discontinue prohibited medications administered for the relief of pain of FMS or for depression and known to induce drowsiness for the required washout period and throughout the study.
- •3. Subject has had non-drug therapies for fibromyalgia (such as herbal or holistic medications) or any other special procedures for fibromyalgia (e.g. TENS, acupuncture) within two weeks prior to the time of randomisation or will not be able to forgo these therapies/procedures during the study. Stable exercise regimens may be continued if subjects have been on them for at least 2 weeks prior to the randomisation.
- •4. Known history of hypersensitivity or intolerance to acetaminophen/paracetamol.
- •5. Withdrawal, introduction, or change in dose of HRT and/or any drug known to substantially inhibit CYP1A2 (e.g., ciprofloxacin, cimetidine, Hormone Replacement Therapy) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrolment.
- •6. Taking any medication with the potential for pharmacokinetic interaction with ropinirole.
- •7. Prior exposure to ropinirole during a previous clinical trial for any indication.
- •8. Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological (other than FMS), or cardiovascular disease or active malignancy (other than basal cell cancer)
- •9. Any abnormality, at Screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG.
- •10. Subject has any clinically significant medical history or abnormality found on physical examination, laboratory assessment or ECG, which in the opinion of the investigator, could interfere with the interpretation of efficacy or safety data, or which otherwise would contraindicate participation in a clinical study.
- •7. ECG or clinical evidence of atrial or ventricular hypertrophy; intraventricular conduction defects (excluding incomplete right bundle branch block in the absence of clinical evidence of heart disease); symptomatic coronary artery disease (or any symptomatic cardiac disease); myocardial strain, ischaemia, or infarct; atrial arrhythmia (must be in normal sinus rhythm); second- or third-degree AV block; congestive heart failure; cor pulmonale; or any cardiac condition that the investigator feels may predispose the subject to ischaemia or arrhythmia
- •Subject has symptoms of a major depressive episode or active significant psychiatric disorders. Subjects with a history of depression that has required ongoing, current treatment with antidepressants are excluded.
- •9. History of clinically significant drug or alcohol abuse as defined by DSM-IV or is unable to refrain from substance abuse throughout the study.
- •12. Use of any investigational drug within 4 weeks (or 5 half-lives, whichever is longer) prior to the Screening Visit or is currently participating in another clinical study in which the subject is or will be exposed to an investigational or non-investigational drug or device.
- •13. History of hypersensitivity or intolerance to ropinirole or associated excipients or dopamine.
- •14. Pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjectsRheumatoid arthritisEUCTR2005-001977-82-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma.Persistent AsthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-001713-42-SEGlaxoSmithKline Research & Development600
进行中（未招募）
1 期
A study to test whether different doses of BI 1291583 help people with bronchiectasisMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersbronchiectasisEUCTR2021-003304-41-HUBoehringer Ingelheim RCV GmbH & Co KG240
进行中（未招募）
1 期
A study to test whether different doses of BI 1291583 help people with bronchiectasisMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersbronchiectasisEUCTR2021-003304-41-PLBoehringer Ingelheim RCV GmbH & Co KG240
尚未招募
不适用
Testosterone to treat men with painful osteoarthritis of the kneeMusculoskeletal - OsteoarthritisKnee OsteoarthritisACTRN12619001691134awley Pharmaceuticals Pty Ltd30